GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Elite Pharmaceuticals Inc (OTCPK:ELTP) » Definitions » EV-to-FCF

Elite Pharmaceuticals (Elite Pharmaceuticals) EV-to-FCF : -45.91 (As of May. 03, 2024)


View and export this data going back to 2009. Start your Free Trial

What is Elite Pharmaceuticals EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Elite Pharmaceuticals's Enterprise Value is $133.55 Mil. Elite Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.91 Mil. Therefore, Elite Pharmaceuticals's EV-to-FCF for today is -45.91.

The historical rank and industry rank for Elite Pharmaceuticals's EV-to-FCF or its related term are showing as below:

ELTP' s EV-to-FCF Range Over the Past 10 Years
Min: -146.98   Med: -16.16   Max: 1182.22
Current: -47.07

During the past 13 years, the highest EV-to-FCF of Elite Pharmaceuticals was 1182.22. The lowest was -146.98. And the median was -16.16.

ELTP's EV-to-FCF is ranked worse than
100% of 511 companies
in the Drug Manufacturers industry
Industry Median: 22.95 vs ELTP: -47.07

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-03), Elite Pharmaceuticals's stock price is $0.12981. Elite Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $0.011. Therefore, Elite Pharmaceuticals's PE Ratio for today is 11.80.


Elite Pharmaceuticals EV-to-FCF Historical Data

The historical data trend for Elite Pharmaceuticals's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Elite Pharmaceuticals EV-to-FCF Chart

Elite Pharmaceuticals Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -12.36 -42.27 21.21 4.92 -10.62

Elite Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8.03 -10.62 -8.44 -86.99 -49.69

Competitive Comparison of Elite Pharmaceuticals's EV-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Elite Pharmaceuticals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Elite Pharmaceuticals's EV-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Elite Pharmaceuticals's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Elite Pharmaceuticals's EV-to-FCF falls into.



Elite Pharmaceuticals EV-to-FCF Calculation

Elite Pharmaceuticals's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=133.549/-2.909
=-45.91

Elite Pharmaceuticals's current Enterprise Value is $133.55 Mil.
Elite Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.91 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Elite Pharmaceuticals  (OTCPK:ELTP) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Elite Pharmaceuticals's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.12981/0.011
=11.80

Elite Pharmaceuticals's share price for today is $0.12981.
Elite Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.011.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Elite Pharmaceuticals EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Elite Pharmaceuticals's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Elite Pharmaceuticals (Elite Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
165 Ludlow Avenue, Northvale, NJ, USA, 07647
Elite Pharmaceuticals Inc is a pharmaceutical company. It is principally engaged in the development and manufacture of oral, controlled-release products, using proprietary know-how and technology. The company's operating segment includes Abbreviated New Drug Applications (ANDA) and New Drug Applications (NDA). It generates maximum revenue from the ANDA segment. The company focuses on developing pain management products; manufacturing a line of generic pharmaceutical products with approved Abbreviated New Drug Applications; developing additional generic pharmaceutical products; development of other products in its pipeline including the products with its partners; and commercialization of new products.
Executives
Mark N Pellegrino officer: CFO, Secretary, Treasurer 165 LUDLOW AVE, NORTHVALE NJ 07647
Kirko Kirkov officer: Chief Commercial Officer 165 LUDLOW AVE, NORTHVALE NJ 07647
Chen Robert C J officer: CFO, Secretary, Treasurer 165 LUDLOW AVENUE, NORTHVALE NJ 07647
Marc Bregman officer: CFO, Secretary, Treasurer C/O ELITE PHARMACEUTICALS, INC., 165 LUDLOW AVENUE, NORTHVALE NJ 07647
Eugene M Pfeifer director C/O ELITE PHARMACEUTICALS, INC, 165, NORTHVALE NJ 07647
Davis S Caskey director C/O ELITE PHARMACEUTICALS, INC, 165 LUDLOW AVE, NORTHVALE NJ 07647
Jerry Treppel director 93 SETON HIGHLANDS, PLYMOUTH MA 02360
Mikah Pharma, Llc 10 percent owner 165 LUDLOW AVE., NORTHVALE NJ 07647
Douglas Plassche officer: Executive VP of Operations 165 LUDLOW AVE., NORTHVALE NJ 07647
Jeenarine Narine director, 10 percent owner C/O EPIC PHARMA, LLC, 227-15 NORTH CONDUIT AVENUE, LAURELTON NY 11413
Ashok G Nigalaye director, 10 percent owner, officer: Chief Scientific Officer C/O EPIC PHARMA, LLC, 227-15 NORTH CONDUIT AVENUE, LAURELTON NY 11413
Epic Pharma Llc 10 percent owner 227-15 NORTH CONDUIT AVE, LAURELTON NY 11413-3134
Epic Investments, Llc 10 percent owner 227-15 NORTH CONDUIT AVENUE, LAURELTON NY 11413
Nasrat A Hakim director, 10 percent owner, officer: President & CEO C/O ELITE PHARMACEUTICALS, INC., 165 LUDLOW AVE., NORTHVALE NJ 07647
Jeffrey A Whitnell director C/O ELITE PHARMACEUTICALS, INC, 165 LUDLOW AVENUE, NORTHVALE NJ 07647

Elite Pharmaceuticals (Elite Pharmaceuticals) Headlines

From GuruFocus